Multimodality approach in bladder cancer management Multimodality approach in bladder cancer...•...

ALLPPT.com _ Free PowerPoint Templates, Diagrams and Charts

นพ.พชัิย จันทร์ศรีวงศ์

นพ.วเิชียร ศริิธนะพล

ผศ.นพ.พทิยา ด่านกุลชัย

Multimodality approach in

bladder cancer management

Outline

MDT in MIBC

Cystectomy

Neoadjuvant and adjuvant chemotherapy

Adjuvant RT

Bladder preservation and CCRT

M1 disease

• 74-year-old male smoker with hypertension who presents with painless gross hematuria.

• He has no known drug allergies and current medications include hydrochlorothiazide.

• He has no known family history of cancer • Physical examination is normal/unremarkable. • Work up :

– Cystoscopy – CT scans – Urine cytology.

Pathology

• TURBT : High grade TCC, invade Muscular layer, no perineural invasion, no lymphovascular invasion.

Lab

• CBC : Hct 33 WBC 7300/mm3 ( N 55%) Plt 220,000 • BUN 19 mg/dl Cr 1.25 mg/dl • LFT : normal • Albumun 39.4 g/L

CT scans chest and whole abdomen

• Lung clear, Liver: no mass • Bladder; multiple enhancing polypoid lesions at poeterior wall of urina

ry bladder abutting bilateral UVJ. • Lesions at left side posterior wall measure 16.5 x 13.4 mm. T3 lesions,

No hydronephrosis. • Lymph node : no enlargement, Bone : no lesions • Staging T3N0M0

29/7/2017

AJCC cancer staging

What are appropriate options for muscle invasive bladder

A. Radical cystectomy (RC) then adjuvant chemotherapy B. Neoadjuvant chemotherapy then cystectomy C. Trimodality therapy : bladder sparing D. CCRT , not done RC E. Partial cystectomy

Cystectomy or adding neo-adjuvant chemotherapy

• Cystectomy

Neoadjuvant treatment

Peri-operative chemotherapy : Rationale

• Deaths from TCC are generally not local events • Patients die as a result of metastatic disease • Local interventions will not deal with micro-metastatic disease • Systemic therapy neoadjuvant or adjuvant must be given to improve

cure rates

Neoadjuvant

NEOADJUVANT CHEMOTHERAPY

THE JOURNAL OF UROLOGY, Vol. 177, 437-443, February 2007

MVAC

CMV

Tolerability of cisplatin-based neo-adjuvant

chemotherapy and effect on radical cystectomy

• MVAC regimen: The mortality rate in patients assigned to chemo was 1%, but drug delivery was excellent with only 20%.

• In the USA, gemcitabine and cisplatin (GC), but there is no level 1 evidence. drug delivery exceeding 90%.

No RCT in using GC in neo-adjuvant

NAC does NOT increase the risk of perioperative morbidity

Presented By Maria De Santis at 2017 Genitourinary Cancers Symposium

HD MVAC toxicity

Toxicity Grade

MVAC (n=129)

(%)

HD MVAC

(n=134)

(%) p

Neutropenia 3 46 12 <0.001

4 16 8

Neutropenic fever 26 10 <0.001

1 case of toxic death in each arm Less WBC toxicity in HD MVAC likely secondary to GCSF Toxicities otherwise similar

Sternberg Eur Urol 2006

#ASCO 2014 - Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC)

in (MIBC): Final results of a multicenter phase II study

• Patients had cT2-T4a, were node negative, and had GFR > 50. • Dose-dense GC was administered as follows:

– gemcitabine 1200 mg/m2 – cisplatin 70 mg/m2 on day one – with pegfilgrastim 6 mg on day 2 or 3.

• This cycle was repeated q 2 weeks, x 3 cycles.

#ASCO2014 –

Neoadjuvant DDGC in (MIBC): Final results

• 31 evaluable patients • 30 underwent radical cystectomy, 32% had a pCR, and 13% were downstaged

to non-muscle invasive disease. • pCR rates are similar to those achieved with accelerated MVAC

• Significantly greater toxicity, particularly vascular toxicity including

DVT, stroke, MI, and PE.

Split dose Cis/Gem – real life data

Presented By Maria De Santis at 2017 Genitourinary Cancers Symposium

Carboplatin in Neoadjuvant

• Not recommendation in using carboplatin in neoadjuvant treatment ( not eligible for cisplatin based chemotherapy)

Carboplatin in Neoadjuvant

• Not recommendation in using carboplatin in neoadjuvant treatment ( not eligible for cisplatin based chemotherapy)

Key points on Neo-adjuvant chemotherapy

• MDT case conference for invasive TCC patients • Patient selection is critical : Not all patients are appropriate • Patients who are offered neo-adjuvant treatment:

– Tend to be younger (<65) – Better PS (ECOG 0-1) – Good renal function (GFR >40)

Adjuvant treatment

• Chemotherapy

• Radiotherapy

Role of Adjuvant chemotherapy

Adjuvant treatment

Value of Adjuvant chemotherapy

Immediate vs Defer

HR 0.77

Adjuvant in T2N0

• pT2 or less and have no nodal involvement or LVI : not recommended to receive adjuvant chemotherapy

Cystectomy is life changing

Resection : en bloc removal of ant pelvic organ, including bladder, prostate in men, TAH+ BSO+ vaginal cuff in women, pelvic LN dissection

Urinary diversion: Intestinal conduit draining into: A. an external collecting bag B. neobladder

Cystectomy is life changing

Morbidity: Memorial Sloan Kettering experience of 1142 cases High volume surgeons:

No cystectomy

• Bladder preservation ( stills need operation ) • CCRT ( say no for operation: palliative aims)

– Chemo alone – Rt alone – Only TURBT

Role of adjuvant RT and

Bladder preservation

Bladder preservation: Med

Does TMT compare with RC?

Survival After Curative therapy

Cox Regression Analysis of OS

Candidates for preservation

• Solitary tumor <5 cm

• Clinical stage T2-T3a ( not indicate for T4)

• No CIS

• No hydronephrosis

• No evidence of LN or distant mets

• Normally functioning bladder

Team and Co-operation

Does Age Matter? • Pooled RTOG MIBC studies : DSS for age < 75 vs Age ≥ 75

Improving CR over time

Concurrent Chemotherapy is important to the success

Doublet

BC2001: Phase 3 of CCRT vs RT in MIBC

RTOG 0233: randomized phase 2

OS : RTOG 0233

QoL after TMT

MGH Urodynamics and QoL study

MGH/UNC : long term QoL

• Six validated QoL questionnaires, scored out of 100

MGH/UNC : long term QoL

CCRT

Role of pre-op CCRT: Phase 3 trials of neoadjuvant chemotherapy

Study group Neoadjuvant arm Standard arm Patients (n) Survival

Australia/United

Kingdom DDP/RT RT 255 No difference

Canada/NCIC DDP/RT or preop RT + Cyst RT/preop RT + Cyst 99 No difference

Spain (CUETO) DDP/Cyst Cyst 121 No difference

EORTC/MRC CMV/RT or Cyst RT or Cyst 976 5.5% difference in favor of CMV

SWOG M-VAC/Cyst Cyst 307 Trend in survival benefit with M-

VAC (p=0.06)

Italy (GUONE) M-VAC/Cyst Cyst 206 No difference

Italy (GISTV) M-VEC/Cyst Cyst 171 No difference

Genoa DDP/5FU/RT/Cyst Cyst 104 No difference

Nordic 1 ADM/DDP/RT/Cyst RT/Cyst 311 No difference, 15% benefit with

ADM + DDP in T3-T4a

Nordic 2 MTX/DDP/Cyst Cyst 317 No difference

Abol-Enein CarboMV/Cyst Cyst 194 Benefit with CarboMV

From Calabro Eur Urol 2009

• T2-T4a NXMO • 2 cycles comprising cisplatin 70 mg/m2 and doxorubicin 30 mg/m2, Q 3-week

• Locally irradiated with 4 Gy daily for 5 consecutive days. • 5-year OS improvement of 15% only for T3–T4 disease compared with RT or Sx

alone (P = 0.03)

• while no survival benefit was found for early stage disease (T1–T2). • Not compare for RT+chemo vs chemo

Preop-CCRT

• Canadian randomized study • Concurrent CDDP improved pelvic disease control with preoperative

CCRT compared with RT alone (P = 0.038). • Preoperative CCRT or RT may be an option treatment for T3–T4a,

especially in who are not candidates for or decline cystectomy

M1 treatment

Overall response rate ( 55% vs 43%, P.0031)

OS 15.8 vs 12.7 Mo (HR 0.85, P .075 NS)

Second-line chemotherapy for muscle

invasive bladder cancer:

• There are no definitive recommendations for second-line

therapy

• Chemotherapy options may include drugs such as

cisplatin, gemcitabine, pemetrexed, carboplatin,

vinblastine, and bleomycin.

• In May 2016, the FDA approval of 1st OI: atezolizumab

vi

vinflunine

OS 6.9 vs 4.6 months

Vinflunine vs BSC

• Chemotherapy in M1 prolongation OS to 12-13

mo VS 3-4 mo in BSC

• 3-year survival: 15-20%

Immuno-Oncology Developments

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

Updated Efficacy From IMvigor210: <br />Atezolizumab in Platinum-Treated Locally Advanced/Metastatic Urothelial Carcinoma (mUC)

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

IMvigor210 Cohort 2: Study Design<br />Basis for Accelerated Approval

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

KEYNOTE-045: Open-Label, Phase 3 Study of Pembrolizumab vs Investigator’s Choice of Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Advanced Urothelial Cancer

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

KEYNOTE-045 Study Design (NCT02256436)

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

Overall Survival: Total

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

Atezolizumab Duvalumab

Nivolumab

Confirmed Objective Response Rate

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

combined positive score (CPS) ≥10% for

PD-L1 expression.

10.3

Atezolizumab as 1L Therapy in Cisplatin-Ineligible Locally Advanced/Metastatic Urothelial Carcinoma: IMvigor210 Cohort 1

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

1st line in cisplatin ineligible

Unfit for Cisplatin

IC 0 ( < 1%), IC1 (≥ 1%- ≤ 5%), IC2/3 (≥ 5%)

OS 14.8 months

14.8

15.3

12.3

Mutation load associated with ORR

Frontline Therapy for UC: Cis-Ineligible

Presented By Matthew Milowsky at 2017 Genitourinary Cancers Symposium

2nd line

IC2/3 (≥ 5%)

11.1 vs 10.6

Systemic Therapy for Bladder Cancer Now

Presented By Elizabeth Plimack at 2016 ASCO Annual Meeting

LBA4 RANGE

• Phase III Docetaxel +/- Ramucirumab in platinum-refractory TCC

• ➢ Positive trial for PFS but difference is modest, OS data are awaited • ➢ Current standard for 2nd-line metastatic urothelial cancer is

checkpoint inhibition

• ➢ Uncertain benefit in the 3rd line setting (after first-line platinum, second-line checkpoint inhibition)

Take home massage • Bladder cancer is genomically complex

• Neoadjuvant produces 5% absolute benefit in survival, need for

MDT in care.

• Trimodality increase Qol, but need MDT and case selection

• Combination chemo can prolong symptoms free and OS in

advanced bladder cancer, but, high levels of toxicity.

– Select treatments for patients: fit or unfit patients

• Ongoing need to improve treatment in bladder cancer, Checkpoint

inhibitor emerges the high efficacy in mTCC.